Arkolith/Insider Trading/ELVN/Form 4

Kintz Samuel

PRESIDENT AND CEO, DirectorEnliven Therapeutics, Inc. (ELVN) · full profile →Form 4 · filed Nov 19, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$273K
Net Open-Market Flow
-$273K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 17, 2025Sell(S)13K$21.82$273K890K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001967168-25-000008) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML